Try our mobile app

General information

Country: UNITED STATES

Sector: Drug Manufacturers — General

Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products for humans and animals. The Company products are sold in countries around the world. Eli Lilly products include neuroscience, endocrine, anti-infectives, cardiovascular agents, oncology, and animal health products.
Website: lilly.com


  • Good financial results growth rate 46.6% (average between last period year over year growth for revenue and EBITDA), there is acceleration compared to average historical growth rates (22.4%)
  • Dividend yield for the last twelve months 0.7%
  • Free cash flow yield -0.9% (LTM)
  • Share price is 227.1% higher than minimum and 20.0% lower than maximum for the last 3 years
  • The company is overvalued by EV / LTM EBITDA multiple compared to target level (50.3x vs
    )
  • Fundamental value created in LTM (estimate)
  • For the last 3 months insiders sold company shares on $0.7 mln (0.000% of cap.)

Key Financials (Download financials)

Ticker: LLY
Share price, USD:  (+1.3%)767.76
year average price 805.75  


year start price 570.39 2023-12-23

min close price 570.39 2023-12-23

max close price 960.02 2024-08-30

current price 767.76 2024-12-21
Common stocks: 903 782 000

Dividend Yield:  0.7%
FCF Yield LTM: -0.9%
EV / LTM EBITDA: 50.3x
EV / EBITDA annualized: 44.3x
Last revenue growth (y/y):  +36.0%
Last growth of EBITDA (y/y):  +57.3%
Historical revenue growth:  +14.5%
Historical growth of EBITDA:  +30.3%
Target EV / EBITDA (hist percentile):
Express share price potential:
Fundamental value created in LTM:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 693 888
Net Debt ($m): 22 389
EV (Enterprise Value): 716 277
EBITDA LTM ($m): 14 235
EV / LTM EBITDA: 50.3x
Price to Book: 48.7x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2024-12-21fool.com

Is Now a Good Time to Buy the Dip in Eli Lilly Stock?

2024-12-20reuters.com

Lilly's weight-loss drug Zepbound wins US FDA approval for sleep apnea

2024-12-20cnbc.com

FDA approves Eli Lilly's weight loss drug Zepbound for sleep apnea, expanding use in U.S.

2024-12-20prnewswire.com

FDA approves Zepbound® (tirzepatide) as the first and only prescription medicine for moderate-to-severe obstructive sleep apnea in adults with obesity

2024-12-20fool.com

Why Novo Nordisk Stock Got Destroyed Today, but Eli Lilly and Viking Stocks Are Up

2024-12-20zacks.com

LLY Stock Up as FDA Removes Mounjaro, Zepbound From Shortage List

2024-12-20businesswire.com

Indiana Sees $39 Billion Worth of Projects Under Construction, an Industrial Info News Alert

2024-12-19reuters.com

Focus: In weight loss battle, Novo and Lilly face growing offensive from licenced copies

2024-12-19reuters.com

US FDA says Lilly's weight-loss drug shortage resolved

2024-12-19cnbc.com

FDA says Eli Lilly's weight loss drug Zepbound is no longer in shortage
More information for subscribed users:
detailed calculation of
Potential and Created Value,
website traffic data